Dicerna Pharmaceuticals (NASDAQ:DRNA) Lifted to “Hold” at BidaskClub

Dicerna Pharmaceuticals (NASDAQ:DRNA) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, BidAskClub reports.

A number of other analysts also recently issued reports on DRNA. SunTrust Banks decreased their price target on Dicerna Pharmaceuticals to $20.00 and set a “buy” rating for the company in a report on Thursday, May 16th. Citigroup lifted their target price on Dicerna Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. ValuEngine upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, June 11th. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. Finally, B. Riley set a $24.00 target price on Dicerna Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $21.57.

Shares of NASDAQ DRNA opened at $14.05 on Tuesday. The stock has a market cap of $965.24 million, a P/E ratio of -11.71 and a beta of 2.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. The business’s 50-day simple moving average is $14.47. Dicerna Pharmaceuticals has a 1 year low of $9.31 and a 1 year high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). The business had revenue of $5.68 million for the quarter, compared to analysts’ expectations of $10.95 million. Dicerna Pharmaceuticals had a negative return on equity of 48.98% and a negative net margin of 737.93%. Equities analysts anticipate that Dicerna Pharmaceuticals will post -1.39 earnings per share for the current year.

In other news, Director Bain Capital Life Sciences Inv sold 1,600,000 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $12.50, for a total transaction of $20,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 21.28% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Dicerna Pharmaceuticals by 8.9% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,618 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 945 shares during the period. Quantamental Technologies LLC increased its position in Dicerna Pharmaceuticals by 94.4% in the 2nd quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,700 shares during the period. Cubist Systematic Strategies LLC increased its position in Dicerna Pharmaceuticals by 7.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 28,161 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 1,871 shares during the period. Charles Schwab Investment Management Inc. increased its position in Dicerna Pharmaceuticals by 0.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 302,337 shares of the biopharmaceutical company’s stock valued at $4,762,000 after acquiring an additional 1,881 shares during the period. Finally, Bank of America Corp DE increased its position in Dicerna Pharmaceuticals by 30.3% in the 4th quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 2,465 shares during the period. Hedge funds and other institutional investors own 85.08% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Read More: Percentage Gainers

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.